Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 14;13(22):5698.
doi: 10.3390/cancers13225698.

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors

Lionel Larribère  1   2   3 , Uwe M Martens  1   4
Affiliations
Review

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors

Lionel Larribère et al. Cancers (Basel). .

Abstract

The ability to detect minimal residual disease (MRD) after a curative-intent surgery or treatment is of paramount importance, because it offers the possibility to help guide the clinical decisions related adjuvant therapy. Thus, the earlier MRD is detected, the earlier potentially beneficial treatment can be proposed to patients who might need it. Liquid biopsies, and in particular the next-generation sequencing of circulating tumor DNA (ctDNA) in the blood, have been the focus of an increasing amount of research in the past years. The ctDNA detection at advanced cancer stages is practicable for several solid tumors, and complements molecular information on acquired therapy resistance. In the context of MRD, it is by definition more challenging to detect ctDNA, but it is technically achievable and provides information on treatment response and probability of relapse significantly earlier than standard imaging methods. The clinical benefit of implementing this new technique in the routine is being tested in interventional clinical trials at the moment. We propose here an update of the current use of ctDNA detection by NGS as a tool to assess the presence of MRD and improve adjuvant treatment of solid tumors. We also discuss the main limitations and medium-term perspectives of this process in the clinic.

Keywords: adjuvant therapy; ctDNA; liquid biopsy; minimal residual disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Workflow of ctDNA NGS in the settings of minimal residual disease (MRD).
See this image and copyright information in PMC

References

    1. Thierry A.R., EI Messaoudi S., Gahan P.B., Anker P., Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35:347–376. doi: 10.1007/s10555-016-9629-x. NON-THEMATIC REVIEW. - DOI - PMC - PubMed
    1. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., Thornton K., Agrawal N., Sokoll L., Szabo S.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008;14:985–990. doi: 10.1038/nm.1789. - DOI - PMC - PubMed
    1. Pisetsky D.S., Fairhurst A.-M. The origin of extracellular DNA during the clearance of dead and dying cells. Autoimmunity. 2009;40:281–284. doi: 10.1080/08916930701358826. - DOI - PubMed
    1. Tabernero J., Lenz H.-J., Siena S., Sobrero A., Falcone A., Ychou M., Humblet Y., Bouché O., Mineur L., Barone C., et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: A retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16:937–948. doi: 10.1016/S1470-2045(15)00138-2. - DOI - PMC - PubMed
    1. Parseghian C.M., Loree J.M., Morris V.K., Liu X., Clifton K.K., Napolitano S., Henry J.T., Pereira A.A., Vilar E., Johnson B., et al. Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge. Ann. Oncol. 2019;30:243–249. doi: 10.1093/annonc/mdy509. - DOI - PMC - PubMed

LinkOut - more resources